PAX Financial Group’s Cytokinetics CYTK Stock Holding History

PAX Financial Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,454	Closed	-$532K	–	179
2022 Q1	$532K	Buy	+14,454	New	+$514K	0.12%	131

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

PAX Financial Group's CYTK Position: Q2 2022 in Review

PAX Financial Group sold out of Cytokinetics (CYTK) in Q2 2022, closing a stake of 14,454 shares — an estimated $532K sold.

PAX Financial Group first reported a position in CYTK in Q1 2022 and held it in 1 quarter. The position peaked at $532K in Q1 2022. 262 funds tracked by Wall St. Rank hold CYTK as of Q2 2022.

PAX Financial Group reported no remaining Cytokinetics position as of Q2 2022 after selling out during the quarter.
PAX Financial Group sold 14,454 Cytokinetics shares in Q2 2022, an estimated $532K.
PAX Financial Group first reported a position in Cytokinetics in Q1 2022 and held it in 1 quarter.
PAX Financial Group's Cytokinetics position peaked at $532K in Q1 2022.
262 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2022.

Based on PAX Financial Group's 13F filing for Q2 2022, filed 9 Aug 2022.